Drugs' Price Increases Lack Evidence
This is a U.S. news story, published by Yahoo Finance, that relates primarily to Cabometyx news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsCabometyx news
For more Cabometyx news, you can click here:
more Cabometyx newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
influential drug pricing watchdog. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest costliest drugs news, expenditure drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
expensive drugsReuters
•Unsupported price hikes added $815 million to US drug spending in 2023
80% Informative
Institute for Clinical and Economic Review ( ICER ) said five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence.
Gilead 's HIV drug Biktarvy , Novartis ' heart drug Entresto, Exelixis' cancer therapy Cabometyx and Pfizer 's rheumatoid arthritis drug Xeljanz were the other four drugs.
VR Score
91
Informative language
99
Neutral language
39
Article tone
formal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links